News
From lab to market: the fourth edition of the Accelerator Meeting Point promotes Bellvitge’s biomedical innovation
The most innovative projects in the healthcare and biomedical sector were presented on December the 16th at the fourth edition of the Accelerator Meeting Point (AMP), organized by the Business Development and Innovation Area of the Biomedical Research Institute of Bellvitge (IDIBELL). The fourth edition of the AMP has counted on the participation of AIISEM, […]
New diagnostic technique for HPV detection in oropharyngeal cancers
The new trial allows human papilloma virus (HPV) detection and genotyping with the same sensitivity as other commonly used PCRs but following a much simpler procedure.
Scientists describe how vaccination has affected bacterial variants that cause pneumonia
Un estudio del IDIBELL y el Hospital Universitario de Bellvitge ha descrito como las vacunas han cambiado la distribución de los distintos serotipos de neumococo.
Scientists discover an essential mechanism for maintaining bone density
A research group of IDIBELL and UB has revealed the importance of the function of NRF2, a protein that regulates the expression of some genes in response to oxidative radicals, in the maintenance of bone tissue.
IDIBELL and Shenzhen Bay Laboratory launch an international exchange program for predoctoral researchers
The new program, following IDIBELL’s strategic plan, aims to promote interaction between both institutions and reinforce scientific collaboration.
New clinical trial for adrenoleukodystrophy, a rare disease of brain metabolism
The IDIBELL Neurometabolic Diseases team, which is also part of CIBERER, plans to start the study in early 2022 with the anti-inflammatory dimethyl fumarate in patients with this condition.
Sara Hijazo was awarded for the best ‘oral communication’ at the XIV Congress of Lung Cancer
Under the title, “Re-definition of lung adenocarcinoma transcriptional subtypes using integrative bioinformatic approaches”, David Cordero, Ania Alay, Raúl Marín, Xavier Solé, and Ernest Nadal have collaborated in the work.
In adverse conditions, tumor cells create ribosome reservoirs that allow them to survive
According to a study by IDIBELL and the University of Barcelona, when the levels of nutrients and energy decrease, tumor cells are able to detect it and enter a low-energy mode, during which they store all the necessary material to later reactivate their growth.
The spin-off Aptadel selected to be part of BCN Health Booster
Aptadel comprise the first generation of companies accelerated at the BCN Health Booster, an initiative promoted by the University of Barcelona (UB), Barcelona Science Park (PCB) and the Barcelona City Council, with support from Barcelona Activa and collaboration from Biocat. The project was created under the Barcelona Science Plan and is an example of collaboration […]